Navigation Links
Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:4/29/2013

BASKING RIDGE, N.J., April 29, 2013 /PRNewswire/ -- Regado Biosciences, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock.  The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Cowen & Company, LLC and BMO Capital Markets will act as joint book-running managers for the offering.  Canaccord Genuity Inc., Needham & Company, LLC , and Wedbush PacGrow Life Sciences will act as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective.  These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus.  Copies of the preliminary prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com

Contacts:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm , Ph.D./Andrew Mielach 
jdrumm@tiberend.com; (212) 375-2664 
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
2. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
3. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
4. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
5. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
6. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
7. TNI BioTech Files Form 10 with SEC
8. Marrone Bio Innovations Files Patent for a Unique Bacillus Species
9. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
10. NDIS Approval of the Promega PowerPlex(R) Y23 System Enables More Usable Profiles in Less Time
11. Lucintel Profiles Top Five Global Polypropylene Companies: APAC is Expected to Drive Future Industry Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 30, 2016 , ... Doctors in Italy say mesothelioma patients with the ... with lower levels. Surviving Mesothelioma has just posted an article on the new research. ... Genoa and La Spezia, Italy tested the blood serum, tumors, and lung fluid of ...
(Date:5/27/2016)... ... May 27, 2016 , ... PBI-Gordon Corporation is pleased to ... Products. , In his 15-year career with PBI-Gordon, Dave has served in a wide ... was integral in the development and launch of many of PBI-Gordon’s most successful products. ...
(Date:5/26/2016)... and READING, England ... Indegene ( http://www.indegene.com ), a leading global provider ... science, pharmaceutical and healthcare organisations and TranScrip ( ... scientific support throughout the product lifecycle, today announced ... launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has been manufacturing quartz ... all over the globe. Their cute firefly logo has been spreading to more ... makes spectrophotometer calibration standards that never require recalibration. These revolutionary standards have ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):